Ardelyx (ARDX) Competitors

Ardelyx (NASDAQ:ARDX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Which has preferable valuation & earnings, ARDX or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$333.61M	3.16	-$39.14M	-$0.22	-20.05
Krystal Biotech	$290.52M	14.67	$89.16M	$4.16	35.45

Do institutionals & insiders hold more shares of ARDX or KRYS?

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Comparatively, 13.7% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more risk and volatility, ARDX or KRYS?

Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Does the media prefer ARDX or KRYS?

In the previous week, Krystal Biotech had 19 more articles in the media than Ardelyx. MarketBeat recorded 30 mentions for Krystal Biotech and 11 mentions for Ardelyx. Krystal Biotech's average media sentiment score of -0.13 beat Ardelyx's score of -0.19 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Krystal Biotech	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate ARDX or KRYS?

Ardelyx currently has a consensus price target of $10.89, suggesting a potential upside of 146.91%. Krystal Biotech has a consensus price target of $213.75, suggesting a potential upside of 44.93%. Given Ardelyx's higher probable upside, research analysts plainly believe Ardelyx is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is ARDX or KRYS more profitable?

Krystal Biotech has a net margin of 37.17% compared to Ardelyx's net margin of -14.86%. Krystal Biotech's return on equity of 14.64% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-14.86%	-34.45%	-13.81%
Krystal Biotech	37.17%	14.64%	13.28%

Summary

Krystal Biotech beats Ardelyx on 12 of the 15 factors compared between the two stocks.